JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB263907

Anti-IGF1 Receptor antibody [EPR23027-80]

  • RabMAb
  • Recombinant
  • KO Validated
  • 20ul selling size
  • What is this?

5

(1 Review)

|

(5 Publications)

Knockout Tested Rabbit Recombinant Monoclonal IGF1 Receptor antibody. Suitable for IP, Flow Cyt, WB, ICC/IF and reacts with Human samples. Cited in 5 publications.

View Alternative Names

CD221, Insulin-like growth factor 1 receptor, Insulin-like growth factor I receptor, IGF-I receptor, IGF1R

6 Images
Immunocytochemistry/ Immunofluorescence - Anti-IGF1 Receptor antibody [EPR23027-80] (AB263907)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-IGF1 Receptor antibody [EPR23027-80] (AB263907)

Immunofluorescent analysis of 100% Methanol-fixed MCF7 (human breast adenocarcinoma epithelial cell) cells labelling IGF1 Receptor with ab263907 at 1/100 dilution, followed by ab150077 AlexaFluor®488 Goat anti-Rabbit secondary antibody at 1/1000 dilution (Green). Confocal image showing membranous staining in MCF7 cell line. ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) was used to counterstain tubulin at1/200 dilution (Red). The Nuclear counterstain was DAPI (Blue).

Secondary antibody only control : Secondary antibody is ab150077 AlexaFluor®488 Goat anti-Rabbit secondary at 1/1000 dilution.

Flow Cytometry - Anti-IGF1 Receptor antibody [EPR23027-80] (AB263907)
  • Flow Cyt

Unknown

Flow Cytometry - Anti-IGF1 Receptor antibody [EPR23027-80] (AB263907)

Flow cytometric analysis MCF7 (human breast adenocarcinoma epithelial cell) cells labelling IGF1 Receptor with ab263907 at 1/500 dilution (Red) compared with a Rabbit monoclonal IgG (ab172730) / Black isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue). A Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) at 1/2000 dilution was used as the secondary antibody.

Gated on viable cells.

Immunoprecipitation - Anti-IGF1 Receptor antibody [EPR23027-80] (AB263907)
  • IP

Unknown

Immunoprecipitation - Anti-IGF1 Receptor antibody [EPR23027-80] (AB263907)

IGF1 Receptor was immunoprecipitated from 0.35 mg MCF7 (human breast adenocarcinoma epithelial cell) whole cell lysate with ab263907 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab263907 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/5000 dilution.

Lane 1 : MCF7 (human breast adenocarcinoma epithelial cell) whole cell lysate 10ug

Lane 2 : ab263907 IP in MCF7 whole cell lysate

Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab263907 in MCF7 whole cell lysate

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

Exposure time : 3 min.

All lanes:

Immunoprecipitation - Anti-IGF1 Receptor antibody [EPR23027-80] (ab263907)

Predicted band size: 154 kDa

Observed band size: 130 kDa

false

Western blot - Anti-IGF1 Receptor antibody [EPR23027-80] (AB263907)
  • WB

Lab

Western blot - Anti-IGF1 Receptor antibody [EPR23027-80] (AB263907)

Lanes 1- 2 : Merged signal (red and green). Green - ab263907 observed at 100 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (ab8245) observed at 37 kDa.

ab263907 was shown to react with IGF1 Receptor in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line ab264801 (knockout cell lysate ab256951) was used. Wild-type HeLa and IGF1R knockout HeLa cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab263907 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-IGF1 Receptor antibody [EPR23027-80] (ab263907) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

IGF1R knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human IGF1R (IGF1 Receptor) knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-igf1r-igf1-receptor-knockout-hela-cell-line-ab264801'>ab264801</a>)

Predicted band size: 154 kDa

Observed band size: 100 kDa

false

Western blot - Anti-IGF1 Receptor antibody [EPR23027-80] (AB263907)
  • WB

Lab

Western blot - Anti-IGF1 Receptor antibody [EPR23027-80] (AB263907)

False colour image of Western blot : Anti-IGF1 Receptor antibody [EPR23027-80] staining at 1/1000 dilution, shown in green; Mouse anti-CANX [CANX/1543] (ab238078) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab263907 was shown to bind specifically to IGF1 Receptor. A band was observed at 105-125 kDa (alpha chain) in wild-type MCF7 cell lysates with no signal observed at this size in IGF1R knockout cell line. To generate this image, wild-type and IGF1R knockout MCF7 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.

All lanes:

Western blot - Anti-IGF1 Receptor antibody [EPR23027-80] (ab263907) at 1/1000 dilution

Lane 1:

Wild-type MCF7 cell lysate at 20 µg

Lane 2:

IGF1R knockout MCF7 cell lysate at 20 µg

Lane 3:

HeLa cell lysate at 20 µg

Lane 4:

HDLM-2 cell lysate at 20 µg

Observed band size: 105-125 kDa

false

Western blot - Anti-IGF1 Receptor antibody [EPR23027-80] (AB263907)
  • WB

Unknown

Western blot - Anti-IGF1 Receptor antibody [EPR23027-80] (AB263907)

Blocking and dilution buffer : 5% NFDM/TBST.

Exposure time : 10 seconds.

The expression profile & molecular weight observed is consistent with what has been described in the literature (PMID : 21807868, 28591735).

Note : the bands larger than 200kDa are Pro-IGF1R.

Low expression cell line : MDA-MB-231 (PMID : 28591735).

All lanes:

Western blot - Anti-IGF1 Receptor antibody [EPR23027-80] (ab263907) at 1/1000 dilution

Lane 1:

A431 (human epidermoid carcinoma epithelial cell) whole cell lysate at 20 µg

Lane 2:

HepG2 (human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg

Lane 3:

HeLa (human cervix adenocarcinoma epithelial cell) whole cell lysate at 20 µg

Lane 4:

MDA-MB-231 (human breast adenocarcinoma epithelial cell) whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 154 kDa

Observed band size: 130 kDa,200 kDa

false

  • Carrier free

    Anti-IGF1 Receptor antibody [EPR23027-80] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR23027-80

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

IP, WB, ICC/IF, Flow Cyt

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "<p></p>", "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1/500", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100", "ICCIF-species-notes": "<p></p>" }, "Mouse": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Rat": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The IGF1 Receptor often referred to as IGF-1R is a transmembrane receptor protein composed of alpha and beta subunits. Studies indicate that the IGF1R protein is involved in mediating the effects of insulin-like growth factor 1 (IGF-1) and plays an important role in cellular signaling. It has a molecular weight of approximately 180 kDa and is widely expressed in various tissues with high concentrations in the liver muscle and brain. Being a tyrosine kinase receptor IGF1R plays an essential role in growth and metabolism.
Biological function summary

IGF1R contributes to several cellular processes including cell proliferation differentiation and survival. This receptor forms a complex upon ligand binding and undergoes autophosphorylation to activate intracellular signaling cascades. IGF1R activation recruits and phosphorylates insulin receptor substrates enabling the downstream signaling pathways that promote cell growth and survival. Its function in cellular responses makes it a focal point in understanding cell biology.

Pathways

IGF1R holds a central position in the PI3K/AKT and MAPK signaling cascades. These pathways play significant roles in cellular growth proliferation and survival. IGF1R phosphorylates various downstream effectors such as IRS-1 and Shc linking it to the activation of AKT and ERK respectively. Therefore it shares pathways with related proteins like the insulin receptor highlighting its importance in mediating similar biological responses.

IGF1R has been implicated in cancers and diabetes. Overexpression of IGF1R has been observed in various malignancies including breast cancer where it relates to resistance in treatment and poor prognosis with cell lines like MCF-7 often being studied in this context. Additionally disruptions in IGF1R signaling link to insulin resistance an important feature of type 2 diabetes. These connections make IGF1R a potential therapeutic target with IGF1R inhibitors currently under exploration to address these health challenges.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways : the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.. When present in a hybrid receptor with INSR, binds IGF1. PubMed : 12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed : 16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.
See full target information IGF1R

Publications (5)

Recent publications for all applications. Explore the full list and refine your search

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 12:e2406965 PubMed39698844

2024

Delayed Administration of IGFBP7 Improved Bone Defect Healing via ZO-1 Dependent Vessel Stabilization.

Applications

Unspecified application

Species

Unspecified reactive species

Shiyu Sun,Yao Li,Yuman Li,Yuting Niu,Zhewen Hu,Chenyu Deng,Yiming Chen,Bo Hu,Ying Huang,Xuliang Deng

PloS one 19:e0313867 PubMed39570927

2024

Single-cell sequencing reveals transcriptional dynamics regulated by ERα in mouse ovaries.

Applications

Unspecified application

Species

Unspecified reactive species

Qicai Hu,Yiqian Gui,Congcong Cao,Jun Xie,Huiru Tang

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 40:2425318 PubMed39505692

2024

MiR-19b-3p inhibits cell viability and proliferation and promotes apoptosis by targeting IGF1 in KGN cells.

Applications

Unspecified application

Species

Unspecified reactive species

Youzhu Li,Yuanyuan Ye,Hengyuan Zhang,Ye Yang,Ningqing Zhang,Hong Gao,Rongfeng Wu

Bioengineered 13:6293-6308 PubMed35212614

2022

Circular RNA midline-1 (circMID1) promotes proliferation, migration, invasion and glycolysis in prostate cancer.

Applications

WB

Species

Human

Yafei Ding,Mi Wang,Jinjian Yang

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 141:415-426 PubMed33116033

2020

miR-520b Inhibits IGF-1R to Increase Doxorubicin Sensitivity and Promote Cell Apoptosis in Breast Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Hui Zhang,Xiao-Dong Zheng,Xiao-Hua Zeng,Li Li,Qi Zhou
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com